Meta-analysis of 8 RCTs (3,978 patients, ER+/HER2- advanced breast cancer): novel oral SERDs did not significantly improve PFS overall vs standard treatment (HR 0.80, p=0.09); benefit in the ESR1-mutated subgroup (HR 0.57). Grade ≥3 TRAEs higher (RR 1.64).
Meta-analysisn = 3,978
Kirmani et al. Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials